Related Experiment Video

Updated: Dec 20, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.7K

Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era

Giuseppe Lassandro1, Valentina Palladino1, Giovanni C D Vecchio1

  • 1Department of Biomedical Science and Human Oncology-Pediatric Unit, University of Bari "Aldo Moro", Bari, Italy.

Endocrine, Metabolic & Immune Disorders Drug Targets
|June 1, 2020
PubMed

Insights

Thrombopoietin receptor agonists (TPO-RAs) effectively treat childhood immune thrombocytopenia (ITP) by increasing platelet counts and reducing bleeding. These TPO-RAs offer a safe and well-tolerated option for pediatric ITP management.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Pharmacology

Background:

  • Immune thrombocytopenia (ITP) is a prevalent bleeding disorder in children.
  • Current management strategies for pediatric ITP are debated, necessitating individualized patient care.
  • Thrombopoietin receptor agonists (TPO-RAs) present a promising therapeutic avenue.

Purpose of the Study:

  • To elucidate the role of TPO-RAs in managing pediatric ITP.
  • To review the efficacy and safety of eltrombopag and romiplostim in children with ITP.

Main Methods:

  • Systematic review of randomized trials and clinical practice data.
  • Focus on the application of TPO-RAs in pediatric ITP management.

Main Results:

  • TPO-RAs (eltrombopag, romiplostim) demonstrate efficacy in pediatric ITP.
  • Treatment with TPO-RAs leads to increased platelet counts and reduced bleeding.
  • Patients treated with TPO-RAs report improved quality of life with a favorable safety profile.

Conclusions:

  • TPO-RAs are effective treatment options for pediatric ITP.
  • While generally well-tolerated, long-term efficacy and safety require further study.
  • Clinical adoption of TPO-RAs for pediatric ITP is increasing.
Abstract

Keywords:
Eltrombopagchildrenimmune thrombocytopeniaplateletsromiplostimthrombopoietin receptor agonists

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
370
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
205
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728